Welcome to our dedicated page for Pharmadrug news (Ticker: lmlld), a resource for investors and traders seeking the latest updates and insights on Pharmadrug stock.
PharmaDrug Inc. (symbol: LMLLD) is a specialty pharmaceutical company that focuses on the research, development, and commercialization of controlled substances, natural medicines, psychedelics, and previously approved drugs. The company recently acquired SecureDose Synthetics Inc., a pharmaceutical research and development company that develops synthetic formulations of existing drugs for potential commercialization. PharmaDrug aims to develop safe supply chains by producing biosynthetic versions of substances that are currently being contaminated with lethal substances like fentanyl. With collaborations in place and ongoing R&D activities, PharmaDrug is working towards developing intellectual property and novel formulations of existing drugs to address drug abuse issues.
Rhea-AI Summary
PharmaDrug Inc. announces a proposed non-brokered private placement offering of units to raise up to $326,000. Each unit will be comprised of one common share and one-half of one common share purchase warrant. The proceeds will be used for general corporate purposes, and certain insiders of the company may participate in the offering. If insiders participate, the company will be issuing securities to purchasers considered 'related parties.'
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) is a specialty pharmaceutical company focusing on controlled-substances and natural medicines, including psychedelics. The company recently acquired Securedose Synthetics Inc., a private pharmaceutical research and development company. The CEO emphasized the vision and strategy behind the acquisition, aiming to develop biosynthetic versions of drugs to address substance abuse and fentanyl contamination issues. The company also granted stock options to external consultants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
-
Rhea-AI Summary
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) announces the successful completion of a debt restructuring, exchanging $1,219,768 of indebtedness for new unsecured convertible debentures with a principal amount of $1,280,756. The debentures mature in one year, with an option to extend the maturity date up to two times for one-year extensions each time. The debentures bear interest at a rate of 12% per annum payable quarterly and may be converted into units at a price of $0.05 per Unit. The Company has also settled $227,658.03 of indebtedness with certain service providers through the issuance of 4,553,160 common shares at a deemed issue price of $0.05. Additionally, the Company confirms that it will not be issuing additional common share purchase warrants to the holders of the company's secured convertible debentures as referenced in the November 7, 2023 press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
Rhea-AI Summary
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) Grants 6.25M Stock Options at $0.055 Exercise Price
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.13%
Tags
-
Rhea-AI Summary
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) has successfully closed the acquisition of Securedose Synthetics Inc., making SecureDose a wholly-owned subsidiary of PharmaDrug.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
-
Rhea-AI Summary
PharmaDrug Inc. announces the acquisition of SecureDose Synthetics Inc. The acquisition will be completed in early November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
70%
Tags
FAQ
What is the focus of PharmaDrug Inc.?
PharmaDrug Inc. is focused on the research, development, and commercialization of controlled substances, natural medicines, psychedelics, and previously approved drugs.
What recent acquisition did PharmaDrug Inc. make?
PharmaDrug Inc. recently acquired SecureDose Synthetics Inc., a pharmaceutical research and development company that specializes in developing synthetic formulations of existing drugs for potential commercialization.
What is PharmaDrug Inc.'s strategy to address drug abuse issues?
PharmaDrug Inc. aims to develop biosynthetic versions of substances to be manufactured domestically in a regulated and pharmaceutical supply chain to create safe supply chains.
What is PharmaDrug Inc.'s collaboration focus?
PharmaDrug Inc. has collaborations in place with a third party regulated university-affiliated lab to continue its R&D activities in developing intellectual property and novel formulations of existing drugs.
What are the benefits of developing biosynthetic versions of substances?
PharmaDrug Inc. believes that biosynthetic versions of substances can be produced domestically in a regulated and pharmaceutical supply chain, offering advantages in terms of safe supply chains and scalable production.
Pharmadrug Inc.